Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.6K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.5K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.5K
Neural Regulation01:37

Neural Regulation

45.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
45.1K
Human Genetics01:28

Human Genetics

1.9K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phosphoproteomic profiling reveals post-translational dysregulation in Huntington's disease patient-derived neurons.

Cellular & molecular biology letters·2026
Same author

Investigating the ageing-Parkinson's disease nexus: standardisation of in vitro models and techniques by the PD-AGE network.

NPJ Parkinson's disease·2025
Same author

Reprogramming Stars #22: Cellular Reprogramming as a Route for Decoding Neurodegenerative Disorders-An Interview with Dr. Janelle Drouin-Ouellet.

Cellular reprogramming·2025
Same author

Disease-specific interventions: The use of cell and gene therapies for Parkinson disease.

Handbook of clinical neurology·2024
Same author

Preface.

Handbook of clinical neurology·2024
Same author

Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington's disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol.

BMJ open·2024

Related Experiment Video

Updated: Apr 16, 2026

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

10.8K

Dopamine and Huntington's disease.

Laetitia C Schwab1, Shady N Garas, Shaady N Garas

  • 1John van Geest Centre for Brain Repair, University of Cambridge, E.D. Adrian Building, Forvie Site, Robinson Way, Cambridge, CB2 0PY, UK.

Expert Review of Neurotherapeutics
|March 17, 2015
PubMed
Summary

Huntington's disease (HD) involves dopamine system dysfunction. This review explores how understanding central dopaminergic pathways could improve treatments for this progressive neurodegenerative disorder.

Keywords:
Huntington’s diseasedopaminedopamine receptormotor disorderstriatum

More Related Videos

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
11:26

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake

Published on: September 21, 2017

13.2K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.7K

Related Experiment Videos

Last Updated: Apr 16, 2026

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

10.8K
Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
11:26

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake

Published on: September 21, 2017

13.2K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.7K

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder with motor, cognitive, and psychiatric symptoms.
  • Dopamine (DA) system dysfunction, affecting DA release and receptors, is implicated in HD.
  • Current HD treatments primarily use anti-dopaminergic agents, assuming motor symptoms stem from overactive dopaminergic pathways.

Purpose of the Study:

  • To review current knowledge of central dopaminergic pathways in HD.
  • To examine how dopaminergic dysfunction contributes to both motor and non-motor symptoms.
  • To explore the mechanisms of action for current dopaminergic therapies and identify treatment paradoxes.

Main Methods:

  • Literature review of pre-clinical and clinical studies on dopamine in HD.
  • Analysis of the role of dopaminergic systems in HD pathogenesis and symptomology.
  • Examination of the efficacy and underlying mechanisms of anti-dopaminergic drugs in HD.

Main Results:

  • Dopaminergic dysfunction is a key feature of HD, impacting various pathways.
  • The precise role of dopamine in HD may evolve with disease progression.
  • Dopaminergic system abnormalities may contribute to non-motor symptoms, which significantly affect quality of life.

Conclusions:

  • Understanding central dopaminergic pathways in HD is crucial for effective treatment.
  • Addressing paradoxes in dopaminergic system function may reveal novel therapeutic strategies.
  • Further research could uncover how dopaminergic drugs impact HD progression and pathogenesis, potentially offering new hope for this incurable disease.